医学
靶向治疗
食品药品监督管理局
癌症
肿瘤科
融合基因
加药
内科学
酪氨酸激酶抑制剂
癌症治疗
基因
癌症研究
药理学
生物化学
化学
作者
Gabriela Mota-George,Susan Schneider
标识
DOI:10.1188/21.cjon.181-187
摘要
Background: Although neurotrophic tyrosine receptor kinase (NTRK) gene fusions are not common in most cancers, they are present in more than 90% of some rare tumors. The U.S. Food and Drug Administration has approved larotrectinib for patients with NTRK gene fusion–positive cancers that meet certain criteria. With ongoing advancements in tumor sequencing, it is anticipated that cancer treatment will be determined by genetic variants rather than by cancer type in the future. Objectives: This article provides an overview of larotrectinib, a targeted therapy. Methods: This article reviews clinical trial results and highlights implications for oncology nurses caring for patients taking larotrectinib. Findings: Larotrectinib is an effective treatment option for some patients with NTRK gene fusion–positive cancers. Oncology nurses are key to educating patients on dosing, administration, side effects, and precautions.
科研通智能强力驱动
Strongly Powered by AbleSci AI